Axsome Jumps 6% as Auvelity Prescriptions Hit Record High

Price ActionProduct / Tech
โดย Seeking Alpha·US·Read original
Summary · why it matters

Axsome Therapeutics shares rose about 6% in Friday trading after data showed prescriptions for Auvelity reached a record high. Data from Symphony Health, part of HealthVerity, found that scripts for the depression and Alzheimer's disease agitation treatment hit roughly 23,500 this week. The US FDA granted the Alzheimer's agitation indication in late April. Mizuho analyst Graig Suvannavejh, who rates Axsome at outperform, said that while it is still early days in the launch, this appears highly indicative of a strong start for Auvelity in ADA.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 1 stocks
Axsome Therapeutics Inc
AXSM
▲ PositiveDemandrelevance

Auvelity prescriptions hit a record ~23,500 this week, indicating strong end-customer demand for the drug.

Financials▲ · 1 stocks

Off-coverage companies 1

HealthVerityPrivate± Mixed
relevance

© 2026 MarketDXNews